JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy

References

• Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108:479–485. doi:10.1038/bjc.2012.581.
   PubMed Web of Science ®Google Scholar
• Szikriszt B, Poti A, Pipek O, Krzystanek M, Kanu N, Molnar J, Ribli D, Szeltner Z, Tusnády GE, Csabai I, et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol. 2016;17:99. doi:10.1186/s13059-016-0963-7.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood. 2002;100:4325–4336. doi:10.1182/blood-2002-03-0772.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N, TJ L, Miller C, Ding L, BJ R, AJ M. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–2074.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa1516192.
   PubMed Web of Science ®Google Scholar
• Levis M. Midostaurin approved for FLT3-mutated AML. Blood. 2017;129:3403–3406. doi:10.1182/blood-2017-05-782292.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–731. doi:10.1182/blood-2017-04-779405.
   PubMed Web of Science ®Google Scholar
• Saultz JN, Garzon R. Acute myeloid leukemia: a concise review. J Clin Med. 2016;5:33-49.
   Web of Science ®Google Scholar
• Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027–1036. doi:10.1056/NEJMoa1010222.
   PubMed Web of Science ®Google Scholar
• Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer. 2011;2:95–107.
   PubMedGoogle Scholar
• Gutierrez SE, Romero-Oliva FA. Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol. 2013;6:57. doi:10.1186/1756-8722-6-57.
   PubMed Web of Science ®Google Scholar
• Prada-Arismendy J, Arroyave JC, Rothlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31:63–76. doi:10.1016/j.blre.2016.08.005.
   PubMed Web of Science ®Google Scholar
• Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506–510. doi:10.1038/nature10738.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
   PubMed Web of Science ®Google Scholar
• Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015;6:6169.
   PubMed Web of Science ®Google Scholar
• Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008;112:1366–1373. doi:10.1182/blood-2007-11-126227.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97:1172–1179. doi:10.1182/blood.V97.5.1172.
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C, Turner BM. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19:1751–1759. doi:10.1038/sj.leu.2403910.
   PubMed Web of Science ®Google Scholar
• Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, Furukawa Y. Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J Biol Chem. 2009;284:30673–30683. doi:10.1074/jbc.M109.042242.
   PubMed Web of Science ®Google Scholar
• Xu X, Xie C, Edwards H, Zhou H, Buck SA, Ge Y, Pandey S. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS One. 2011;6:e17138. doi:10.1371/journal.pone.0017138.
   PubMed Web of Science ®Google Scholar
• Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 2013;33:2989–2996.
   PubMed Web of Science ®Google Scholar
• Lee YG, Kim I, Yoon SS, Park S, Cheong JW, Min YH, Lee J-O, Bang S-M, Yi HG, Kim CS, et al. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol. 2013;161:339–347. doi:10.1111/bjh.12256.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32:2601–2613. doi:10.1038/onc.2012.347.
   PubMed Web of Science ®Google Scholar
• Qing Y, Stark GR. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem. 2004;279:41679–41685. doi:10.1074/jbc.M406413200.
   PubMed Web of Science ®Google Scholar
• Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, et al. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Oncotarget. 2017;8:47103–47109. doi:10.18632/oncotarget.17482.
   PubMedGoogle Scholar
• Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M, et al. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J. 2015;5:e335. doi:10.1038/bcj.2015.63.
   PubMed Web of Science ®Google Scholar
• Bray LJ, Binner M, Korner Y, von Bonin M, Bornhauser M, Werner C. A three-dimensional ex vivo tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche. Haematologica. 2017;102:1215–1226. doi:10.3324/haematol.2016.157883.
   PubMed Web of Science ®Google Scholar
• Aljitawi OS, Li D, Xiao Y, Zhang D, Ramachandran K, Stehno-Bittel L, Van Veldhuizen P, Lin TL, Kambhampati S, Garimella R, et al. A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells. Leuk Lymphoma. 2014;55:378–391. doi:10.3109/10428194.2013.793323.
   PubMed Web of Science ®Google Scholar
• Blanco TM, Mantalaris A, Bismarck A, Panoskaltsis N. The development of a three-dimensional scaffold for ex vivo biomimicry of human acute myeloid leukaemia. Biomaterials. 2010;31:2243–2251. doi:10.1016/j.biomaterials.2009.11.094.
   PubMed Web of Science ®Google Scholar
• Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi H-S, van der Kouwe E, Gültekin S, et al. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 2017;4:e595–e606. doi:10.1016/S2352-3026(17)30208-9.
   PubMed Web of Science ®Google Scholar
• Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129(11):e26–e37. doi:10.1182/blood-2016-09-738070.
   PubMed Web of Science ®Google Scholar
• Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, et al. MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. Cancer Discov. 2018;8:478–497. doi:10.1158/2159-8290.CD-17-1271.
   PubMed Web of Science ®Google Scholar
• Anders B, Veltri L, Kanate AS, Shillingburg A, Shah N, Craig M, Cumpston A. Outcomes of six-dose high-dose cytarabine as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia. Adv Hematol. 2017;2017:6464972. doi:10.1155/2017/6464972.
   PubMedGoogle Scholar
• Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 2010; 51:73–78.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh A, Khodadi E, Shahjahani M, Bertacchini J, Vosoughi T, Saki N. The Role of HDACs as Leukemia Therapy Targets using HDI. Int J Hematol Oncol Stem Cell Res. 2015;9:203–214.
   PubMedGoogle Scholar
• Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18:1414–1438.
   Web of Science ®Google Scholar
• DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27:1628–1636. doi:10.1038/leu.2013.38.
   PubMed Web of Science ®Google Scholar
• Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4:e170. doi:10.1038/bcj.2013.68.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, Wang Y, Balusu R, Chen J, Koul S, et al. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther. 2009;8:939–950. doi:10.4161/cbt.8.10.8213.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, et al. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts. Leukemia. 2017;31:2799–2806. doi:10.1038/leu.2017.159.
   PubMed Web of Science ®Google Scholar
• Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, et al. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood. 2013;121:4366–4376. doi:10.1182/blood-2012-10-464149.
   PubMed Web of Science ®Google Scholar
• Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, Lamba JK, Huang RS, Dolan ME. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009;113:2145–2153. doi:10.1182/blood-2008-05-154302.
   PubMed Web of Science ®Google Scholar
• Alvarez JV, Frank DA. Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther. 2004;3:1045–1050. doi:10.4161/cbt.3.11.1172.
   PubMed Web of Science ®Google Scholar
• Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117:5701–5709. doi:10.1182/blood-2010-04-280123.
   PubMed Web of Science ®Google Scholar
• Sepulveda P, Encabo A, Carbonell-Uberos F, Minana MDBCL-2. expression is mainly regulated by JAK/STAT3 pathway in human CD34+ hematopoietic cells. Cell Death Differ. 2007;14:378–380. doi:10.1038/sj.cdd.4402007.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Kaestel CG, Eriksen KW, Woetmann A, Stokkedal T, Kaltoft K, Geisler C, Röpke C, Ødum N. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999;13:735–738. doi:10.1038/sj.leu.2401415.
   PubMed Web of Science ®Google Scholar
• Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, Li L, Gooden F, Korenchuk S, Hou XS, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008;68(10):3785–3794. doi:10.1158/0008-5472.CAN-07-6091.
   PubMed Web of Science ®Google Scholar
• Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119:4614–4618. doi:10.1182/blood-2011-12-400051.
   PubMed Web of Science ®Google Scholar
• Chen WC, Yuan JS, Xing Y, Mitchell A, Mbong N, Popescu AC, McLeod J, Gerhard G, Kennedy JA, Bogdanoski G, et al. An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers. Cancer Res. 2016;76(5):1214–1224. doi:10.1158/0008-5472.CAN-15-2743.
   PubMed Web of Science ®Google Scholar
• Magina KN, Pregartner G, Zebisch A, Wölfler A, Neumeister P, Greini HT, Berghold A, Sill H. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130(7):946–948. doi:10.1182/blood-2017-04-777722.
   PubMed Web of Science ®Google Scholar
• Brijwani N, Jain M, Dhandapani M, Zahed F, Mukhopadhyay P, Biswas M, Khatri D, Radhakrishna VD, Majumder B, Radhakrishnan P, et al. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. Sci Rep. 2017;7(1):1502. doi:10.1038/s41598-017-01566-x.
   PubMedGoogle Scholar
• Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010;177:415–423. doi:10.2353/ajpath.2010.090863.
   PubMed Web of Science ®Google Scholar
• Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol. 2014;9:221. doi:10.1186/s13000-014-0221-9.
   PubMed Web of Science ®Google Scholar